Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study
Cancer patients are at increased risk of venous thromboembolism (VTE), representing one of the main causes of death. In this paper, we used the ONCOTHROMB12-01 study cohort for the analysis of 18-month overall survival (OS) and cancer-associated venous thrombosis (CAT) cumulative incidence. The OS i...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-10-01
|
| Series: | International Journal of Cardiology: Heart & Vasculature |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352906725001575 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849317315072491520 |
|---|---|
| author | Bárbara Lobato-Delgado Magdalena Ruiz Carme Font Vanessa Pachón Victoria Castellón Virginia Martínez-Marín Mercedes Salgado Eva Martínez Julia Calzas Laura Ortega Ana Rupérez Oriol Pujol José Manuel Soria Andrés Muñoz |
| author_facet | Bárbara Lobato-Delgado Magdalena Ruiz Carme Font Vanessa Pachón Victoria Castellón Virginia Martínez-Marín Mercedes Salgado Eva Martínez Julia Calzas Laura Ortega Ana Rupérez Oriol Pujol José Manuel Soria Andrés Muñoz |
| author_sort | Bárbara Lobato-Delgado |
| collection | DOAJ |
| description | Cancer patients are at increased risk of venous thromboembolism (VTE), representing one of the main causes of death. In this paper, we used the ONCOTHROMB12-01 study cohort for the analysis of 18-month overall survival (OS) and cancer-associated venous thrombosis (CAT) cumulative incidence. The OS is described for patients with and without CAT across age, sex, cancer type, stage and presence of recurrent VTE using the Kaplan-Meier method and log-rank test. Moreover, a Cox regression model with stepwise feature selection is trained to identify predictors of prognosis. Results show an 18-month CAT cumulative incidence of 16.5 % (CI 13.1–21.0 %) and a median OS for patients with CAT of 9.1 months (CI 5.9–12.5). Furthermore, CAT is associated with shorter survival in lung, colorectal and pancreatic cancer in advanced stages, regardless of age and sex; VTE recurrence also reduces survival significantly. The model found ECOG performance status of 2, cancer type, metastatic stage, VTE, mucinous histology and complete tumor resection as meaningful predictors; the latter being the only protective factor. In conclusion, the diagnosis of CAT has a profound impact on OS in the ONCOTHROMB12-01 study regardless of the clinical characteristics of patients. |
| format | Article |
| id | doaj-art-a18daa2fe4f14598afd45053f53df425 |
| institution | Kabale University |
| issn | 2352-9067 |
| language | English |
| publishDate | 2025-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Cardiology: Heart & Vasculature |
| spelling | doaj-art-a18daa2fe4f14598afd45053f53df4252025-08-20T03:51:14ZengElsevierInternational Journal of Cardiology: Heart & Vasculature2352-90672025-10-016010175410.1016/j.ijcha.2025.101754Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort studyBárbara Lobato-Delgado0Magdalena Ruiz1Carme Font2Vanessa Pachón3Victoria Castellón4Virginia Martínez-Marín5Mercedes Salgado6Eva Martínez7Julia Calzas8Laura Ortega9Ana Rupérez10Oriol Pujol11José Manuel Soria12Andrés Muñoz13Unit of Genomics of Complex Diseases, Institut de Recerca Sant Pau (IR Sant Pau), Sant Quintí 77-79, 08041 Barcelona, SpainInstituto de Investigación Gregorio Marañón, Madrid, SpainMedical Oncology, Hospital Clínic, Barcelona, SpainMedical Oncology, Hospital Universitario Ramón y Cajal Madrid, Madrid, SpainMedical Oncology, Complejo Hospitalario de Torrecárdenas, Almería, SpainMedical Oncology, Hospital Universitario La Paz, Madrid, SpainMedical Oncology, Complejo Hospitalario Universitario de Ourense, Ourense, SpainMedical Oncology, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, SpainMedical Oncology, Hospital Universitario de Fuenlabrada, Madrid, SpainUnit of Genomics of Complex Diseases, Institut de Recerca Sant Pau (IR Sant Pau), Sant Quintí 77-79, 08041 Barcelona, SpainMedical Oncology, Hospital Universitario de Toledo, Toledo, SpainUniversitat de Barcelona (UB), Barcelona, SpainUnit of Genomics of Complex Diseases, Institut de Recerca Sant Pau (IR Sant Pau), Sant Quintí 77-79, 08041 Barcelona, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain; Corresponding author at: Unit of Genomics of Complex Diseases, Institut de Recerca Sant Pau (IR Sant Pau), Sant Quintí 77-79, 08041 Barcelona, Spain.Medical Oncology Service. Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain; Cancer and Thrombosis Working Group, Spanish Society of Medical Oncology (SEOM), Madrid, SpainCancer patients are at increased risk of venous thromboembolism (VTE), representing one of the main causes of death. In this paper, we used the ONCOTHROMB12-01 study cohort for the analysis of 18-month overall survival (OS) and cancer-associated venous thrombosis (CAT) cumulative incidence. The OS is described for patients with and without CAT across age, sex, cancer type, stage and presence of recurrent VTE using the Kaplan-Meier method and log-rank test. Moreover, a Cox regression model with stepwise feature selection is trained to identify predictors of prognosis. Results show an 18-month CAT cumulative incidence of 16.5 % (CI 13.1–21.0 %) and a median OS for patients with CAT of 9.1 months (CI 5.9–12.5). Furthermore, CAT is associated with shorter survival in lung, colorectal and pancreatic cancer in advanced stages, regardless of age and sex; VTE recurrence also reduces survival significantly. The model found ECOG performance status of 2, cancer type, metastatic stage, VTE, mucinous histology and complete tumor resection as meaningful predictors; the latter being the only protective factor. In conclusion, the diagnosis of CAT has a profound impact on OS in the ONCOTHROMB12-01 study regardless of the clinical characteristics of patients.http://www.sciencedirect.com/science/article/pii/S2352906725001575CancerCATVTESurvivalCox regressionMachine Learning |
| spellingShingle | Bárbara Lobato-Delgado Magdalena Ruiz Carme Font Vanessa Pachón Victoria Castellón Virginia Martínez-Marín Mercedes Salgado Eva Martínez Julia Calzas Laura Ortega Ana Rupérez Oriol Pujol José Manuel Soria Andrés Muñoz Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study International Journal of Cardiology: Heart & Vasculature Cancer CAT VTE Survival Cox regression Machine Learning |
| title | Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study |
| title_full | Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study |
| title_fullStr | Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study |
| title_full_unstemmed | Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study |
| title_short | Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study |
| title_sort | cancer associated venous thromboembolism and its impact on survival in the oncothromb12 01 cohort study |
| topic | Cancer CAT VTE Survival Cox regression Machine Learning |
| url | http://www.sciencedirect.com/science/article/pii/S2352906725001575 |
| work_keys_str_mv | AT barbaralobatodelgado cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT magdalenaruiz cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT carmefont cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT vanessapachon cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT victoriacastellon cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT virginiamartinezmarin cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT mercedessalgado cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT evamartinez cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT juliacalzas cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT lauraortega cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT anaruperez cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT oriolpujol cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT josemanuelsoria cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy AT andresmunoz cancerassociatedvenousthromboembolismanditsimpactonsurvivalintheoncothromb1201cohortstudy |